FDA panel to review diet drugs | theheart.org
Links shared publicly online about this topic.
- 960total visits
FDA panel to review diet drugs | theheart.org
View full resource at theheart.org
Tags: Metabolic, Obesity Medication, Diet and Nutrition, Drug, FDA, Lorcaserin
Most Recently Shared on August 9, 2010 at 10:25 pm By:
Sibutramine CV safety, lorcaserin, up for FDA review: The FDA's Endocrinologic and Metabolic Drugs Advisory Commit... http://bit.ly/bBPd6l
Weight loss pill Qnexa wins panel vote and awaits approval
news-medical.net — “The drug was rejected in a 10-6 vote the first time it came before a Food and Drug Administration (FDA) advisory panel, in 2010, due to safety concerns. However when the medication returned for another review in February, the advisory committee gave it near-unanimous approval (20-2). Because the FDA often follows the advisory panel's advice, Qnexa is likely to get FDA approval, probably by mid-April.” View full resource at news-medical.net
Most Recently Shared on April 5, 2012 at 11:08 pm By:
Diet News: Weight loss pill Qnexa wins panel vote and awaits approval: The drug was rejected in a 10-6 vote the ... http://t.co/rGbONdEq
FDA notes concerns about Vivus diet pill safety ahead of panel - FierceBiotech
fiercebiotech.com — “U.S. regulators have cited concerns about the safety of Vivus’ ($VVUS) experimental diet pill Qnexa in review documents as the California drug developer pursues the first FDA approval of a Read more...” View full resource at fiercebiotech.com
Most Recently Shared on February 17, 2012 at 3:52 pm By:
FDA notes concerns about Vivus diet pill safety ahead of panel http://t.co/Z8Nc7jXR $VVUS
theheart.org: trusted cardiology news and opinions
theheart.org — “The latest developments in cardiology and cardiovascular research, including breaking heartwire news and commentary by some of the world's most prominent cardiologists.” View full resource at theheart.org
Most Recently Shared on December 7, 2010 at 10:33 pm By:
Most FDA advisors say likely benefits of Contrave diet drug outweigh its cardiovascular risks: In all, 13 panel ... http://bit.ly/hHMhj8
Orexigen ($OREX) braces for a brutal panel review - FierceBiotech
fiercebiotech.com — “Can Orexigen Therapeutics' ($OREX) diet drug Contrave survive the FDA's advisory panel review process? Analysts have been pondering that question now that the FDA is scheduled to release staff Read more...” View full resource at fiercebiotech.com
Most Recently Shared on December 1, 2010 at 3:30 am By:
Orexigen ($OREX) braces for a brutal panel review. http://bit.ly/hSZBo8
Meridia risks warrant restrictions or withdrawal: FDA panel | theheart.org
theheart.org — “UPDATED // Six members of the FDA panel voted to recommend that the FDA severely restrict access to the weight-loss drug, and eight recommended the plug be pulled on it altogether. Only two on the panel reviewing the SCOUT trial concluded that the drug should remain on the market with a boxed warning only, and no members thought the drug could stay with no labeling changes.” View full resource at theheart.org
Most Recently Shared on September 15, 2010 at 8:58 pm By:
Full story on today's #Meridia / sibutramine FDA advisory meeting now @ theheart.org http://www.theheart.org/article/1122267.do
Ticagrelor advisory panel | theheart.org
theheart.org — “FDA's Cardiovascular and Renal Drugs Advisory Committee will review AstraZeneca's new drug application for ticagrelor, the proposed new antiplatelet drug for patients with acute coronary syndrome.” View full resource at theheart.org
Most Recently Shared on July 28, 2010 at 11:57 am By:
#Brilinta. Waiting for the ticagrelor FDA advisory panel to begin. See our preview here: http://bit.ly/aQotet
FDA Panel Votes Against New Diet Drug - ABC News
abcnews.go.com — “An initial review by the U.S. Food and Drug Administration has found the diet pill Qnexa to be safe and effective, according to an FDA report released Tuesday morning.” View full resource at abcnews.go.com
Most Recently Shared on July 16, 2010 at 11:47 am By:
Samantha Heller, RD Nutritionist and Dietitian
FDA Panel Rejects New Diet Drug Qnexa http://abcnews.go.com/Health/WellnessNews/fda-panel-votes-diet-drug/story?id=11173354
F.D.A. Review of Diet Pill Relieves Investors - Prescriptions Blog - NYTimes.com
prescriptions.blogs.nytimes.com — “The regulatory agency released its examination of the safety and effectiveness of Qnexa, in advance of an advisory panel on Thursday.” View full resource at prescriptions.blogs.nytimes.com
Most Recently Shared on July 13, 2010 at 4:49 pm By:
F.D.A. Review of Diet Pill Pleases Investors http://nyti.ms/clTxIo
Advertisement
